BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
BlossomHill Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 18, 2026
$14.16+0.22 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $38.43M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 18, 2026 | Before market open | – | $-8.75 | – |
Press releases
Announcements BlossomHill Therapeutics filed with the SEC
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2
Regulation FD disclosure · EX-99.1 to Form 8-K